Berenguer, D.; Alcover, M.M.; Sessa, M.; Halbaut, L.; Guillén, C.; Boix-Montañés, A.; Fisa, R.; Calpena-Campmany, A.C.; Riera, C.; Sosa, L.
Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity. Pharmaceutics 2020, 12, 149.
https://doi.org/10.3390/pharmaceutics12020149
AMA Style
Berenguer D, Alcover MM, Sessa M, Halbaut L, Guillén C, Boix-Montañés A, Fisa R, Calpena-Campmany AC, Riera C, Sosa L.
Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity. Pharmaceutics. 2020; 12(2):149.
https://doi.org/10.3390/pharmaceutics12020149
Chicago/Turabian Style
Berenguer, Diana, Maria Magdalena Alcover, Marcella Sessa, Lyda Halbaut, Carme Guillén, Antoni Boix-Montañés, Roser Fisa, Ana Cristina Calpena-Campmany, Cristina Riera, and Lilian Sosa.
2020. "Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity" Pharmaceutics 12, no. 2: 149.
https://doi.org/10.3390/pharmaceutics12020149
APA Style
Berenguer, D., Alcover, M. M., Sessa, M., Halbaut, L., Guillén, C., Boix-Montañés, A., Fisa, R., Calpena-Campmany, A. C., Riera, C., & Sosa, L.
(2020). Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity. Pharmaceutics, 12(2), 149.
https://doi.org/10.3390/pharmaceutics12020149